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Methicillin-resistant Staphylococcus aureus (MRSA) was first 
isolated in a culture medium in Europe during the 1960’s. [1] Now 
widespread throughout the world, infection with this organism has 
emerged as a major problem in surgical practice. [2] An audit by the 
Joint Vascular Research Group in Great Britain and Ireland 
demonstrated that the majority of documented wound and graft 
infections in vascular patients were secondary to MRSA. [3] The 
likelihood of developing morbidity and perioperative death was shown 
to be higher in patients with MRSA than those with the other bacterial 
infections.   
MRSA colonization has been reported in 3-20% of vascular 
patients. [4] Many develop infective complications.  Stump infection 
with MRSA increases time to wound healing, augments risk of revision 
amputation and hence duration of hospital stay.[5]  Wound infections 
with other bacteria are not related with worse outcome.[4]  Several 
reports and audits have been published suggesting that MRSA infection 
is associated with worse clinical outcome relative to other 
organisms.[6,7]   
The clinical impact and attributable risks of MRSA infection on the 
vascular surgical patients undergoing lower extremity amputations 
remain unclear.  We reviewed our clinical experience over two-year 
duration with 171 consecutive lower limb amputations, determining the 
incidence of MRSA as well as non-MRSA infections, with the objective of 
establishing relative effect on clinical outcomes.   
 
2. Materials and Methods 
The study was conducted at the Department of General 
Surgery, Royal Wolverhampton NHS trust hospital, Wolverhampton, UK, 
from November 2012 to December 2014. All the patients who 
underwent limb amputation in vascular unit during this time were 
identified through the hospital coding system as well as operation 
theatre register.  176 patients were identified but five had amputations 
of upper limb and these patients were excluded from this study.  
Records of remaining 171 patients with lower extremity amputation 
were reviewed for patient demographics, underlying disease condition, 
presenting symptoms and clinical indication for amputation.  Wound 
class, American Society of Anesthetists (ASA) grade, operative details, 
hospital stay, and microbiology culture reports were also reviewed.  
Follow-up details, including time for stump healing, need for re-
operation or revision, and postoperative complications were recorded.   
The decision for type of amputation and need for any 
adjunctive revascularization was made by the consultant vascular 
surgeons.  Patients with clinically non-salvageable extremities and 
chronically non-ambulatory individuals underwent primary 
amputation.  Operative procedures included removal of all necrotic 
tissue, wide drainage of purulent collections, routine cultures of 
wounds, staged amputation for grossly septic wounds, and meticulous 
haemostasis.  Intravenous antibiotics were routinely administered at 
the time of surgery.  The type and duration of antimicrobial therapy 
were neither uniform nor standardized.  Initial choice was based on the 
consultant’s preference, though it was uniformly modified when culture 
results were available.  Follow-up included regular wound examinations 
until discharge, followed by continued clinical evaluation until complete 
epithelialization of the stump wound was achieved.   
Demographic variables, operative procedure, and clinical course of 
the MRSA-infected patients were compared with the non-MRSA-
infected patients using Fisher’s exact test.  A p value of less than 0.05 
was considered to be statistically significant.   
 
3. Results 
During the two-year review, 171 patients underwent lower 
extremity amputation.  Sixteen patients (9.3%) had documented wound 
infections confirmed through the bacterial cultures.  These were 
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stratified into two groups:  group 1 (n = 10) had positive MRSA cultures, 
while group 2 (n = 6) grew other bacterial flora.  Table 1 outlines the 
patient demographics of the two groups along with comparison with 
the rest of the patients without any wound infection.  No significant 
differences were noted in the clinical features and co-morbid conditions 
between the two groups.  Most of the surgical procedures were 
performed electively by the consultant surgeons.  Operating time varied 
depending upon the level of amputation and seniority of the operating 
surgeon, but there was no statistically significant difference between 
the operating times of the two groups (p = 0.19).   
 














(n = 6)[n (%)] 
Statistical difference 
between MRSA & non-MRSA 
(p value) 
Age in years  
(median  SD) 
75  12.64 71  11.09 68.5  9.66 0.43 
Gender frequency  
(Male: Female) 
99:56 5:5 3:3 N/A 
DM 92 (59.3) 7 (70) 4 (66.6) 0.43 
HTN 113 (72.9) 9 (90) 5 (83.3) 0.88 
Hyperlipidemia 52 (33.5) 3 (30) 2 (33.3) 0.16 
Urgency frequency (Elective: 
Emergency)  
125:30 8:2 5:1 N/A 
Surgeon level frequency  
(Consultant: Registrar) 
100:55 6:4 4:2 N/A 
Operation duration in minutes  
(median  SD) 
60.0  26 62.5  58 77.5  30 0.19 
 
Fisher’s exact test is used.  Level of significance p ≤ 0.05 
SD: standard deviation; DM: diabetes mellitus; HTN: hypertension; N/A: not applicable 
 
All 171 patients underwent lower limb amputation for acute 
or chronic limb ischemia.  Table 2 compares the levels of amputation 
between these groups.  No significant differences were noted in the 
level of amputation between the groups.  On analysis of American 
Society of Anesthetists (ASA) grades of patients developing MRSA & 
non-MRSA infections, 81.2% of patients belonged to ASA grade 3 
(severe systemic disease), 12.5% to ASA grade 2 (mild systemic 
disease) and 6.3% to ASA grade 4 (incapacitating disease).  None was 
seen in ASA grade 1 (no disease) or 5 (moribund).   
 
Table 2:  Comparison of level of amputation in MRSA- and non-MRSA-infected patients undergoing lower limb amputation 
 
 
Level of amputation 
No infection 




(n = 10) [n (%)] 
Group 2 
Non-MRSA infection 
(n = 6) [n (%)] 
Statistical difference 
between MRSA & non-MRSA 
(p value) 
Above-knee (AKA) 51 (32.9) 4 (40) 2 (33) 0.78 
Below-knee (BKA) 38 (24.5) 3 (30) 3 (50) 0.09 
Trans-metatarsal 7 (4.5) 0 0 N/A 
Toe 59 (38.0) 3 (30) 1 (17) 0.57 
 
Fisher’s exact test is used.  Level of significance p ≤ 0.05 
N/A: not applicable 
 
The bacteriology culture results from the study population 
are analyzed in table 3.  MRSA predominated (62.5%), followed by 
methicillin-sensitive Staphylococcus aureus (12.5%), Pseudomonas 
aeruginosa (12.5%), coagulase-negative staphylococci (6.2%) and 
enterococcus (6.2%). Comparison of MRSA and non-MRSA patients 
based on wound classification is shown in Figure 1.  The wounds were 
categorized at the time of surgery into four classes; a clean wound is 
where there is no inflammation, clean-contaminated wound has mild 
inflammation, contaminated wound has non-purulent inflammation, 
and dirty wound contains purulent inflammation. No significant 
increase was seen in the risk of acquiring MRSA infection based on the 
type of surgical wound. 
 
Table 3:  Frequency of organisms isolated from bacterial cultures grown from patients undergoing lower limb amputation. 
 
Organism Incidence [n (%)] 
Methicillin-resistant Staphylococcus aureus (MRSA) 10 (62.5) 
Methicillin-sensitive Staphylococcus aureus (MSSA) 2 (12.5) 
Pseudomonas aeruginosa 2 (12.5) 
Coagulase-negative Staphylococcus 1 (6.2) 
Enterococcus 1 (6.2) 
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Figure 1:  Comparison of MRSA- and non-MRSA-infected patients based on wound classification, with p=0.46 on student’s t-test. 
Level of significance p ≤ 0.05 
 
 
There was no death within 30 day post-operative period in 
all groups within the study. Two patients (20%) with documented 
MRSA infection (group 1) required an amputation to a higher level.  In 
group 2, none required revised amputation, while 5 patients had a 
higher level amputation in no-infection group.  Overall there was no 
significant difference observed between group 1 or 2 in 30-day 
morbidity rates. Over a 28 months median follow-up (range 16-50 
months), an overall survival of 93% was observed.  Twelve patients 
(7%) died including one in MRSA group and 11 in no infection group.   
 
4. Discussion 
MRSA poses not only a serious health-care problem but also a 
notorious public issue.  Many studies have confirmed an increase in the 
prevalence of methicillin resistance among Staphylococcus aureus. [8] In 
a study of European intensive care units, 30% of all infections were 
attributable to S. aureus and 60% of these were MRSA. [9] This study 
also demonstrated that MRSA most commonly affected the ischemic 
limb in the vascular patients undergoing lower extremity amputation, 
although positive blood cultures were not uncommon.   
Several studies have been published demonstrating that 
MRSA infection is associated with worse clinical outcome compared to 
the other organisms. [5-7, 10] Ibelings and Bruining found that patients 
with MRSA infections had lesser chances of survival than those with 
non-MRSA infections. [11] However, these reports and audits also 
observed that patients with MRSA infections often had an increased 
incidence of co-morbid conditions that may itself be associated with 
poor outcome.  No significant difference has been shown in mortality 
between matched MRSA and non-MRSA infected patients. [12] del Rio-
Sola and colleagues found no statistical difference in relation to 
morbidity, mortality, re-amputation rate and mean time of hospital stay 
between well matched MRSA and non-MRSA infected patients 
undergoing lower extremity amputations. [13] The two groups in our 
study were also similarly matched in demographics, indication & level 
of amputation, duration of operation, ASA grades, and wound 
classification.  We did not find any statistical difference between co-
morbid conditions amongst these two groups, including diabetes 
mellitus (p 0.43), hypertension (p 0.88) and hyperlipidemia (p 0.16).  
This explains the lack of significant differences in the 30-day morbidity 
or mortality rates between MRSA- and non-MRSA-infected patients 
reported by our study.   
Despite the development of focused antibiotics against MRSA, 
the most effective approach to reduce MRSA infection involves 
minimizing spread, through infection control measures. [14] 
Introducing practices, such as thorough hand washing, patient isolation, 
and aggressive treatment of affected patients have been shown to 
reduce the transmission of active infection.  A typical combination of 
oral rifampicin and fusidic acid should be used for nosocomial strains of 
MRSA.  All serious MRSA infections should be treated with parenteral 
vancomycin, or if the patient is vancomycin allergic, teicoplanin, which 
remains the antibiotic of choice for initial empirical treatment. New 
antibiotics such as linezolid, pristinamycin and quinupristin have good 
anti-MRSA activity but are very expensive. [15-17]   
 
5. Conclusion 
Irrespective of the dangers commonly associated with MRSA 
infection, the results of this study suggest that patients undergoing 
lower extremity amputation infected by MRSA are at no more increased 
risk of complications than patients with non-MRSA infection with 
similar pre-operative co-morbid conditions.  Therefore, no additional 
interventions seem necessary in patients with MRSA infection.  We 
suggest that regardless of the presence of MRSA bacteria; common 
infection control measures, thorough wound debridement, careful 
wound surveillance and judicial administration of antibiotics be applied 
to all the patients.   
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